Cisplatin-induced hyponatremia

被引:0
|
作者
Peyrade, F
Taillan, B
Lebrun, C
Bendini, JC
Passerron, C
Dujardin, P
机构
[1] HOP CIMIEZ,SERV HEMATOL MED INTERNE,F-06003 NICE,FRANCE
[2] HOP LOUIS PASTEUR,GRP NEUROONCOL,F-06002 NICE,FRANCE
来源
PRESSE MEDICALE | 1997年 / 26卷 / 32期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Cisplatin is one of the most widely used agents in cancer treatment. Cisplatin regimens can lead to a more or less pronounced hyponatremia in 4 to 10% of cases due to salt wasting with hypomagnesemia and normokaliemia. Functional and renal failure and orthostatic hypotension can be observed. CASE REPORT: A 54-year-old woman with brain metastases of a non-small-cell lung cancer was given a chemotherapy regimen containing cisplatin. Hyponatremia mia with confusion occurred after each cisplatin perfusion. The diagnosis retained was cisplatin-induced salt wasting. The patient was given salt prolonged supplementation and carboplatin was substituted for cisplatin in the chemotherapy regimen. DISCUSSION: Hyponatremia frequently occurs in cancer patients. Cisplatin-induced hyponatremia requires specific management Treatment is based on sodium intake which sometimes takes several months to replete stores. Carboplatin can be used instead of cisplatin in case of major hyponatremia. (C) 1997, Masson, Paris.
引用
收藏
页码:1523 / 1525
页数:3
相关论文
共 50 条
  • [41] Efficacy of safranal to cisplatin-induced nephrotoxicity
    Karafakioglu, Yasemin Sunucu
    Bozkurt, Mehmet Fatih
    Hazman, Omer
    Fidan, A. Fatih
    BIOCHEMICAL JOURNAL, 2017, 474 (07) : 1195 - 1203
  • [42] Role of RhoA in Cisplatin-Induced Neurotoxicity
    Friesland, Amy Michelle
    Duenas, Maria
    Weng, Zhiying
    Longo, Frank M.
    Chen, Yan-Hua
    Lu, Qun
    FASEB JOURNAL, 2013, 27
  • [43] Mechanisms of cisplatin-induced muscle atrophy
    Sakai, Hiroyasu
    Sagara, Atsunobu
    Arakawa, Kazuhiko
    Sugiyama, Ryoto
    Hirosaki, Akiko
    Takase, Kazuhide
    Jo, Ara
    Sato, Ken
    Chiba, Yoshihiko
    Yamazaki, Mitsuaki
    Matoba, Motohiro
    Narita, Minoru
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2014, 278 (02) : 190 - 199
  • [44] EFFECT OF THYROXINE ON CISPLATIN-INDUCED NEPHROTOXICITY
    AHN, JH
    KIM, JO
    SHIN, SM
    PARK, YH
    KIDNEY INTERNATIONAL, 1993, 44 (05) : 1178 - 1178
  • [45] CISPLATIN-INDUCED CHANGES IN BLEOMYCIN ELIMINATION
    YEE, GC
    CROM, WR
    CHAMPION, JE
    BRODEUR, GM
    EVANS, WE
    CANCER TREATMENT REPORTS, 1983, 67 (06): : 587 - 589
  • [46] CISPLATIN-INDUCED ATRIAL-FIBRILLATION
    MENARD, O
    MARTINET, Y
    LAMY, P
    JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) : 192 - 193
  • [47] Leteprinim attenuates cisplatin-induced neuropathy
    Reddy, G.
    Mirejovsky, D.
    Lenaz, G.
    Andriambeloson, E.
    Kung, E.
    Schwebel, H.
    Quinton, J.
    Van Hoogevest, P.
    EJC SUPPLEMENTS, 2006, 4 (12): : 69 - 69
  • [48] Cisplatin-induced activation of the EGF receptor
    Moran Benhar
    David Engelberg
    Alexander Levitzki
    Oncogene, 2002, 21 : 8723 - 8731
  • [49] Molsidomine Prevents Cisplatin-induced Hepatotoxicity
    Bentli, Recep
    Parlakpinar, Hakan
    Polat, Alaadin
    Samdanci, Emine
    Sarihan, Mehmet Ediz
    Sagir, Mustafa
    ARCHIVES OF MEDICAL RESEARCH, 2013, 44 (07) : 521 - 528
  • [50] Amelioration of cisplatin-induced nephrotoxicity by statins
    Maheshwari, Rajesh A.
    Sailor, Girish U.
    Patel, Lalji
    Balaraman, R.
    INDIAN JOURNAL OF PHARMACOLOGY, 2013, 45 (04) : 354 - 358